Regulation of beta-amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds

卷:43

Review

关键词: CELLULAR PRION PROTEIN;    NICOTINIC ACETYLCHOLINE-RECEPTOR;    GLYCATION END-PRODUCTS;    A-BETA;    MEMORY IMPAIRMENT;    OXIDATIVE STRESS;    TRANSGENIC MICE;    GAMMA-SECRETASE;    AGGREGATION INHIBITOR;    MOUSE MODEL;   

DOI  :  10.1002/med.21947

来源: SCIE

【 摘 要 】

Alzheimer's disease (AD) is a progressive neurodegenerative disease that is difficult to treat. Extracellular amyloid is the principal pathological criterion for the diagnosis of AD. Amyloid beta (A beta) interacts with various receptor molecules on the plasma membrane and mediates a series of signaling pathways that play a vital role in the occurrence and development of AD. Research on receptors that interact with A beta is currently ongoing. Overall, there are no effective medications to treat AD. In this review, we first discuss the importance of A beta in the pathogenesis of AD, then summarize the latest progress of A beta-related targets and compounds. Finally, we put forward the challenges and opportunities in the development of effective AD therapies.

【 授权许可】

Free